• / Free eNewsletters & Magazine
  • / My Account

High Risk

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Global Lightning Protection System Market - Forecasts and Opportunity Assessment by Technavio

    Global Lightning Protection System Market - Forecasts and Opportunity Assessment by Technavio

  2. Senate Health Care Bill Fails to Adequately Protect People with Cystic Fibrosis

    Senate Health Care Bill Fails to Adequately Protect People with Cystic Fibrosis

  3. MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Tennessee

    MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Tennessee

  4. UPDATE: Do you need to pay off your mortgage before you retire?

    UPDATE: Do you need to pay off your mortgage before you retire?

  5. RepRisk Data Incorporated into Ecolab’s Water Risk Monetizer

    RepRisk Data Incorporated into Ecolab’s Water Risk Monetizer

  6. Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia

    Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia

  7. Can AstraZeneca Thrive on Its Own? Big Test Looms

    Can AstraZeneca Thrive on Its Own? Big Test Looms

  8. Social SafeGuard Announces New Connectors to Support WhatsApp and Facebook Events

    Social SafeGuard Announces New Connectors to Support WhatsApp and Facebook Events

  9. UPDATE: When Bill Gates and Mark Zuckerberg sound the same dire warning about jobs, it's time to listen

    UPDATE: When Bill Gates and Mark Zuckerberg sound the same dire warning about jobs, it's time to listen

  10. New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High -Risk Melanoma Patients Presented at ASCO

    New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High - Risk Melanoma Patients Presented at ASCO

12345

©2017 Morningstar Advisor. All right reserved.